This year's tenth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research was presented for outstanding, novel, and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer, or the treatment of patients with cancer.
Riverview, Michigan, April 18, 2016 – Ash Stevens Inc., a leading provider of global contract pharmaceutical drug substance development and active pharmaceutical ingredient (API) manufacturing services, is pleased to announce the company sponsored a 2016 Award for Outstanding Achievement in Chemistry in Cancer Research, which was presented to James Bradner at the Annual Meeting of American Association for Cancer Research (AACR) this week.
James E. Bradner, MD, who is President of Novartis Institutes for BioMedical Research in Cambridge, Massachusetts, delivered his award lecture titled "Chemical Biology of BET Bromodomains" at the AACR Annual Meeting in New Orleans, Louisiana, on April 16, 2016. A physician-scientist from the Dana-Farber Cancer Institute and Harvard Medical School, Dr. Bradner was appointed President of the Novartis Institutes for BioMedical Research (NIBR) in September of 2015. He is a graduate of Harvard College and the University of Chicago Medical School. Dr. Bradner has co-authored more than 130 scientific publications and 30 United States Patent applications.
Ash Stevens President and Chief Executive Officer, Dr. Stephen A. Munk, stated, "We are very proud to have sponsored this prestigious award. Dr. Bradner’s continued leadership and dedication in the prevention and treatment of cancer is an inspiration; specifically his pioneering studies on the development of new drug treatments and approaches. Dr. Bradner's contributions have led to several first-in-class drug molecules presently in clinical trials."
About Ash Stevens Inc.
Ash Stevens Inc. is a full service pharmaceutical Contract Development and Manufacturing Organization (CDMO) offering comprehensive small-molecule drug substance development and cGMP manufacturing services. Founded in 1962 and headquartered in Riverview, Michigan, Ash Stevens has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs) for Life Science companies developing innovator small-molecule therapeutics. Ash Stevens is a long-time provider of contract research services to the National Institutes of Health and the National Cancer Institute, and has participated in the development of many important drugs developed through these government agencies. To date, Ash Stevens has received thirteen FDA manufacturing approvals for innovator APIs, including four fast-track manufacturing approvals for the active ingredients in the oncology drugs Velcade®, Vidaza®, Clolar® and Iclusig®. Services offered by Ash Stevens include process development and scale-up; cGMP manufacturing; development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities (including method development, stability studies and qualification of reference standards); and regulatory support for all phases of drug development and manufacturing